347 related articles for article (PubMed ID: 33383190)
1. Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2.
Shahid M; Shahzad-Ul-Hussan S
J Struct Biol; 2021 Mar; 213(1):107690. PubMed ID: 33383190
[TBL] [Abstract][Full Text] [Related]
2. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.
Freidel MR; Armen RS
PLoS One; 2021; 16(2):e0246181. PubMed ID: 33596235
[TBL] [Abstract][Full Text] [Related]
3. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
4. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
[TBL] [Abstract][Full Text] [Related]
5. Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.
Rajarshi K; Khan R; Singh MK; Ranjan T; Ray S; Ray S
Gene; 2021 Feb; 768():145313. PubMed ID: 33220345
[TBL] [Abstract][Full Text] [Related]
6. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication.
Zhang Y; Tang LV
J Proteome Res; 2021 Jan; 20(1):49-59. PubMed ID: 33347311
[TBL] [Abstract][Full Text] [Related]
7. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
[TBL] [Abstract][Full Text] [Related]
8. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
Suganya S; Divya S; Parani M
Rev Med Virol; 2021 May; 31(3):e2174. PubMed ID: 32965078
[TBL] [Abstract][Full Text] [Related]
10. Targeting novel structural and functional features of coronavirus protease nsp5 (3CL
Roe MK; Junod NA; Young AR; Beachboard DC; Stobart CC
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33507143
[TBL] [Abstract][Full Text] [Related]
11. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
Habtemariam S; Nabavi SF; Banach M; Berindan-Neagoe I; Sarkar K; Sil PC; Nabavi SM
Arch Med Res; 2020 Oct; 51(7):733-735. PubMed ID: 32536457
[TBL] [Abstract][Full Text] [Related]
12. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
13. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
14. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
15. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Cannalire R; Cerchia C; Beccari AR; Di Leva FS; Summa V
J Med Chem; 2022 Feb; 65(4):2716-2746. PubMed ID: 33186044
[TBL] [Abstract][Full Text] [Related]
16. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
17. Virus-, host-, immune-based targets for COVID-19 therapy.
Liu W; Zhu HL; Duan Y
Drug Discov Today; 2020 Dec; 25(12):2071-2073. PubMed ID: 33035666
[No Abstract] [Full Text] [Related]
18. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
19. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
